Home › NDC Lookup › RxCUI directory › RxCUI 1604338

Sodium phosphate, dibasic 60 MG/ML / sodium phosphate, monobasic 160 MG/ML Oral Solution — RxCUI 1604338

RxNorm drug concept · Semantic clinical drug
RxCUI 1604338 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1604338
Official nameSodium phosphate, dibasic 60 MG/ML / sodium phosphate, monobasic 160 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assodium phosphate, dibasic 2.7 GM / sodium phosphate, monobasic 7.2 GM per 45 ML Oral Solution; sodium phosphate, dibasic 2.7 GM / sodium phosphate, monobasic 7.2 GM in 45 mL Oral Solution
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Sodium phosphate, dibasic 60 MG/ML / sodium phos... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sodium phosphate, dibasic 60 MG/ML / sodium phosphate, monobasic 160 MG/ML Oral Solution RxCUI 1604338

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Sodium phosphate, dibasic 236719
    • Sodium phosphate, monobasic 235496
    • Sodium phosphate, dibasic / sodium phosphate, monobasic 817886
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Solution 385024
    • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Liquid Product 1159925
    • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Product 1159926
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • Oral Product 1151131
  3. Clinical & branded drugs 2

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Sodium phosphate, dibasic 60 MG/ML 446567
    • Sodium phosphate, monobasic 160 MG/ML 446568

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sodium phosphate, dibasic 60 MG/ML SCDC · 446567
  • Sodium phosphate, monobasic 160 MG/ML SCDC · 446568
  • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Solution SCDF · 385024
  • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Liquid Product SCDG · 1159925
  • Sodium phosphate, dibasic / sodium phosphate, monobasic Oral Product SCDG · 1159926

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1604338 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55910-0339-24 1 BOTTLE in 1 CARTON (55910-339-24) / 45 mL in 1 BOTTLE Saline Laxative Cherry Laxative Dolgencorp Inc. 2016-03-15
Observed labelers: Dolgencorp Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.